NBSE - NeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02
2023-05-11 17:22:14 ET
- NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q1 GAAP EPS of -$0.12 misses by $0.02 .
- For the quarter ended March 31, 2023, total operating expenses were approximately $4.2 million, consisting of approximately $2.9 million in general and administrative expenses and $1.3 million in research and development expenses.
- As of March 31, 2023, the Company had cash and cash equivalents of approximately $13.8 million, compared with approximately $17.4 million as of December 31, 2022.
For further details see:
NeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02